Copyright Reports & Markets. All rights reserved.

Global Non-benzodiazepine Hypnotics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Non-benzodiazepine Hypnotics by Type
    • 1.3.1 Overview: Global Non-benzodiazepine Hypnotics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Non-benzodiazepine Hypnotics Consumption Value Market Share by Type in 2025
    • 1.3.3 Zolpidem
    • 1.3.4 Zopiclone
    • 1.3.5 Eszopiclone
    • 1.3.6 Zaleplon
  • 1.4 Classification of Non-benzodiazepine Hypnotics by Dosage Form
    • 1.4.1 Overview: Global Non-benzodiazepine Hypnotics Market Size by Dosage Form: 2021 Versus 2025 Versus 2032
    • 1.4.2 Global Non-benzodiazepine Hypnotics Consumption Value Market Share by Dosage Form in 2025
    • 1.4.3 Tablets
    • 1.4.4 Capsules
    • 1.4.5 Other
  • 1.5 Classification of Non-benzodiazepine Hypnotics by Product Status
    • 1.5.1 Overview: Global Non-benzodiazepine Hypnotics Market Size by Product Status: 2021 Versus 2025 Versus 2032
    • 1.5.2 Global Non-benzodiazepine Hypnotics Consumption Value Market Share by Product Status in 2025
    • 1.5.3 Originator Drugs
    • 1.5.4 Generic Drugs
  • 1.6 Global Non-benzodiazepine Hypnotics Market by Application
    • 1.6.1 Overview: Global Non-benzodiazepine Hypnotics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.6.2 Hospitals
    • 1.6.3 Clinics
    • 1.6.4 Other
  • 1.7 Global Non-benzodiazepine Hypnotics Market Size & Forecast
  • 1.8 Global Non-benzodiazepine Hypnotics Market Size and Forecast by Region
    • 1.8.1 Global Non-benzodiazepine Hypnotics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.8.2 Global Non-benzodiazepine Hypnotics Market Size by Region, (2021-2032)
    • 1.8.3 North America Non-benzodiazepine Hypnotics Market Size and Prospect (2021-2032)
    • 1.8.4 Europe Non-benzodiazepine Hypnotics Market Size and Prospect (2021-2032)
    • 1.8.5 Asia-Pacific Non-benzodiazepine Hypnotics Market Size and Prospect (2021-2032)
    • 1.8.6 South America Non-benzodiazepine Hypnotics Market Size and Prospect (2021-2032)
    • 1.8.7 Middle East & Africa Non-benzodiazepine Hypnotics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Cosette Pharmaceuticals
    • 2.1.1 Cosette Pharmaceuticals Details
    • 2.1.2 Cosette Pharmaceuticals Major Business
    • 2.1.3 Cosette Pharmaceuticals Non-benzodiazepine Hypnotics Product and Solutions
    • 2.1.4 Cosette Pharmaceuticals Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Cosette Pharmaceuticals Recent Developments and Future Plans
  • 2.2 Sanofi
    • 2.2.1 Sanofi Details
    • 2.2.2 Sanofi Major Business
    • 2.2.3 Sanofi Non-benzodiazepine Hypnotics Product and Solutions
    • 2.2.4 Sanofi Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Sanofi Recent Developments and Future Plans
  • 2.3 Sumitomo Pharma
    • 2.3.1 Sumitomo Pharma Details
    • 2.3.2 Sumitomo Pharma Major Business
    • 2.3.3 Sumitomo Pharma Non-benzodiazepine Hypnotics Product and Solutions
    • 2.3.4 Sumitomo Pharma Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sumitomo Pharma Recent Developments and Future Plans
  • 2.4 Teva Pharmaceutical Industries
    • 2.4.1 Teva Pharmaceutical Industries Details
    • 2.4.2 Teva Pharmaceutical Industries Major Business
    • 2.4.3 Teva Pharmaceutical Industries Non-benzodiazepine Hypnotics Product and Solutions
    • 2.4.4 Teva Pharmaceutical Industries Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Teva Pharmaceutical Industries Recent Developments and Future Plans
  • 2.5 Viatris
    • 2.5.1 Viatris Details
    • 2.5.2 Viatris Major Business
    • 2.5.3 Viatris Non-benzodiazepine Hypnotics Product and Solutions
    • 2.5.4 Viatris Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Viatris Recent Developments and Future Plans
  • 2.6 Sandoz
    • 2.6.1 Sandoz Details
    • 2.6.2 Sandoz Major Business
    • 2.6.3 Sandoz Non-benzodiazepine Hypnotics Product and Solutions
    • 2.6.4 Sandoz Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Sandoz Recent Developments and Future Plans
  • 2.7 Aurobindo Pharma
    • 2.7.1 Aurobindo Pharma Details
    • 2.7.2 Aurobindo Pharma Major Business
    • 2.7.3 Aurobindo Pharma Non-benzodiazepine Hypnotics Product and Solutions
    • 2.7.4 Aurobindo Pharma Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Aurobindo Pharma Recent Developments and Future Plans
  • 2.8 Sun Pharmaceutical Industries
    • 2.8.1 Sun Pharmaceutical Industries Details
    • 2.8.2 Sun Pharmaceutical Industries Major Business
    • 2.8.3 Sun Pharmaceutical Industries Non-benzodiazepine Hypnotics Product and Solutions
    • 2.8.4 Sun Pharmaceutical Industries Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Sun Pharmaceutical Industries Recent Developments and Future Plans
  • 2.9 Dr. Reddy's Laboratories
    • 2.9.1 Dr. Reddy's Laboratories Details
    • 2.9.2 Dr. Reddy's Laboratories Major Business
    • 2.9.3 Dr. Reddy's Laboratories Non-benzodiazepine Hypnotics Product and Solutions
    • 2.9.4 Dr. Reddy's Laboratories Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Dr. Reddy's Laboratories Recent Developments and Future Plans
  • 2.10 Torrent Pharmaceuticals
    • 2.10.1 Torrent Pharmaceuticals Details
    • 2.10.2 Torrent Pharmaceuticals Major Business
    • 2.10.3 Torrent Pharmaceuticals Non-benzodiazepine Hypnotics Product and Solutions
    • 2.10.4 Torrent Pharmaceuticals Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Torrent Pharmaceuticals Recent Developments and Future Plans
  • 2.11 Lupin
    • 2.11.1 Lupin Details
    • 2.11.2 Lupin Major Business
    • 2.11.3 Lupin Non-benzodiazepine Hypnotics Product and Solutions
    • 2.11.4 Lupin Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Lupin Recent Developments and Future Plans
  • 2.12 Jiangsu Nhwa Pharmaceutical
    • 2.12.1 Jiangsu Nhwa Pharmaceutical Details
    • 2.12.2 Jiangsu Nhwa Pharmaceutical Major Business
    • 2.12.3 Jiangsu Nhwa Pharmaceutical Non-benzodiazepine Hypnotics Product and Solutions
    • 2.12.4 Jiangsu Nhwa Pharmaceutical Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Jiangsu Nhwa Pharmaceutical Recent Developments and Future Plans
  • 2.13 Shanghai Pharmaceuticals
    • 2.13.1 Shanghai Pharmaceuticals Details
    • 2.13.2 Shanghai Pharmaceuticals Major Business
    • 2.13.3 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Product and Solutions
    • 2.13.4 Shanghai Pharmaceuticals Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Shanghai Pharmaceuticals Recent Developments and Future Plans
  • 2.14 Qilu Pharmaceutical
    • 2.14.1 Qilu Pharmaceutical Details
    • 2.14.2 Qilu Pharmaceutical Major Business
    • 2.14.3 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Product and Solutions
    • 2.14.4 Qilu Pharmaceutical Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.14.5 Qilu Pharmaceutical Recent Developments and Future Plans
  • 2.15 Chengdu Kanghong Pharmaceutical Group
    • 2.15.1 Chengdu Kanghong Pharmaceutical Group Details
    • 2.15.2 Chengdu Kanghong Pharmaceutical Group Major Business
    • 2.15.3 Chengdu Kanghong Pharmaceutical Group Non-benzodiazepine Hypnotics Product and Solutions
    • 2.15.4 Chengdu Kanghong Pharmaceutical Group Non-benzodiazepine Hypnotics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.15.5 Chengdu Kanghong Pharmaceutical Group Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Non-benzodiazepine Hypnotics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Non-benzodiazepine Hypnotics by Company Revenue
    • 3.2.2 Top 3 Non-benzodiazepine Hypnotics Players Market Share in 2025
    • 3.2.3 Top 6 Non-benzodiazepine Hypnotics Players Market Share in 2025
  • 3.3 Non-benzodiazepine Hypnotics Market: Overall Company Footprint Analysis
    • 3.3.1 Non-benzodiazepine Hypnotics Market: Region Footprint
    • 3.3.2 Non-benzodiazepine Hypnotics Market: Company Product Type Footprint
    • 3.3.3 Non-benzodiazepine Hypnotics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Non-benzodiazepine Hypnotics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Non-benzodiazepine Hypnotics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Non-benzodiazepine Hypnotics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Non-benzodiazepine Hypnotics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Non-benzodiazepine Hypnotics Consumption Value by Type (2021-2032)
  • 6.2 North America Non-benzodiazepine Hypnotics Market Size by Application (2021-2032)
  • 6.3 North America Non-benzodiazepine Hypnotics Market Size by Country
    • 6.3.1 North America Non-benzodiazepine Hypnotics Consumption Value by Country (2021-2032)
    • 6.3.2 United States Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Non-benzodiazepine Hypnotics Consumption Value by Type (2021-2032)
  • 7.2 Europe Non-benzodiazepine Hypnotics Consumption Value by Application (2021-2032)
  • 7.3 Europe Non-benzodiazepine Hypnotics Market Size by Country
    • 7.3.1 Europe Non-benzodiazepine Hypnotics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 7.3.3 France Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Non-benzodiazepine Hypnotics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Non-benzodiazepine Hypnotics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Non-benzodiazepine Hypnotics Market Size by Region
    • 8.3.1 Asia-Pacific Non-benzodiazepine Hypnotics Consumption Value by Region (2021-2032)
    • 8.3.2 China Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 8.3.5 India Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Non-benzodiazepine Hypnotics Consumption Value by Type (2021-2032)
  • 9.2 South America Non-benzodiazepine Hypnotics Consumption Value by Application (2021-2032)
  • 9.3 South America Non-benzodiazepine Hypnotics Market Size by Country
    • 9.3.1 South America Non-benzodiazepine Hypnotics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Non-benzodiazepine Hypnotics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Non-benzodiazepine Hypnotics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Non-benzodiazepine Hypnotics Market Size by Country
    • 10.3.1 Middle East & Africa Non-benzodiazepine Hypnotics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Non-benzodiazepine Hypnotics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Non-benzodiazepine Hypnotics Market Drivers
  • 11.2 Non-benzodiazepine Hypnotics Market Restraints
  • 11.3 Non-benzodiazepine Hypnotics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Non-benzodiazepine Hypnotics Industry Chain
  • 12.2 Non-benzodiazepine Hypnotics Upstream Analysis
  • 12.3 Non-benzodiazepine Hypnotics Midstream Analysis
  • 12.4 Non-benzodiazepine Hypnotics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Non-benzodiazepine Hypnotics market size was valued at US$ 1216 million in 2025 and is forecast to a readjusted size of US$ 1479 million by 2032 with a CAGR of 2.8% during review period.
    Non-benzodiazepine hypnotics are prescription Z-drugs, primarily including zolpidem, zopiclone, eszopiclone, and zaleplon. Although chemically distinct from conventional benzodiazepines, they mainly produce sedative and hypnotic effects by modulating the GABA_A receptor complex and are used to treat difficulty initiating sleep, frequent nocturnal awakening, early awakening, and sleep-maintenance insomnia. Major dosage forms include immediate-release tablets, extended-release tablets, sublingual tablets, orally disintegrating tablets, capsules, and oral sprays. Upstream inputs mainly include zolpidem tartrate, zopiclone, eszopiclone, and zaleplon active pharmaceutical ingredients, together with pharmaceutical excipients, coating materials, capsule shells, blister packaging, and other pharmaceutical packaging materials. Downstream customers mainly include hospitals, psychiatric and sleep clinics, retail pharmacies, pharmaceutical wholesalers, and regulated online prescription platforms. Generic competition is relatively intense, while differentiated dosage forms and branded products retain higher added value, with an overall gross margin generally ranging from approximately 45% to 68%.
    From the current market perspective, non-benzodiazepine hypnotics have developed into a mature market dominated by zolpidem, with zopiclone and eszopiclone representing important secondary segments and zaleplon accounting for a relatively small share. All major active ingredients are exposed to generic competition, and standard tablets are supplied by numerous manufacturers. Regional structures differ: the United States relies mainly on zolpidem and eszopiclone, zopiclone is more widely used in Europe, Canada, and parts of Asia, and China uses zolpidem, zopiclone, and eszopiclone under controlled-drug manufacturing, distribution, and prescribing requirements.
    Looking ahead, market development will focus increasingly on dosage-form optimization, lower-dose treatment, individualized dosing, and medication safety. Standard tablets will continue to account for most volume, while extended-release tablets, sublingual products, oral sprays, and low-dose products for middle-of-the-night awakening offer greater differentiation. Manufacturers will strengthen risk management relating to next-day impairment, complex sleep behaviors, falls in older patients, and dependence, while improving prescription review, packaging controls, and patient education.
    Key market drivers include faster-paced lifestyles, psychological stress, population aging, psychiatric comorbidities, and improving recognition of sleep disorders. Z-drugs have long-established clinical use, rapid onset, broad physician familiarity, and lower treatment costs than many newer insomnia medicines. These characteristics support continued use in primary care, hospital, and retail prescription markets. Wider generic availability also improves affordability and market access in lower- and middle-income countries.
    The main constraints include risks of tolerance, dependence, misuse, withdrawal, next-day cognitive and motor impairment, and complex sleep behaviors. Many countries impose controlled-drug rules and limits on prescription duration. Cognitive behavioral therapy for insomnia, digital sleep interventions, orexin receptor antagonists, and other new-mechanism treatments will divert some chronic-insomnia patients. In addition, centralized procurement, reimbursement controls, and generic competition will continue to reduce average selling prices, limiting revenue growth despite increasing treatment volume.
    This report is a detailed and comprehensive analysis for global Non-benzodiazepine Hypnotics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Non-benzodiazepine Hypnotics market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Non-benzodiazepine Hypnotics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Non-benzodiazepine Hypnotics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Non-benzodiazepine Hypnotics market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Non-benzodiazepine Hypnotics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Non-benzodiazepine Hypnotics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cosette Pharmaceuticals, Sanofi, Sumitomo Pharma, Teva Pharmaceutical Industries, Viatris, Sandoz, Aurobindo Pharma, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Non-benzodiazepine Hypnotics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Zolpidem
    Zopiclone
    Eszopiclone
    Zaleplon
    Market segment by Dosage Form
    Tablets
    Capsules
    Other
    Market segment by Product Status
    Originator Drugs
    Generic Drugs
    Market segment by Application
    Hospitals
    Clinics
    Other
    Market segment by players, this report covers
    Cosette Pharmaceuticals
    Sanofi
    Sumitomo Pharma
    Teva Pharmaceutical Industries
    Viatris
    Sandoz
    Aurobindo Pharma
    Sun Pharmaceutical Industries
    Dr. Reddy's Laboratories
    Torrent Pharmaceuticals
    Lupin
    Jiangsu Nhwa Pharmaceutical
    Shanghai Pharmaceuticals
    Qilu Pharmaceutical
    Chengdu Kanghong Pharmaceutical Group
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Non-benzodiazepine Hypnotics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Non-benzodiazepine Hypnotics, with revenue, gross margin, and global market share of Non-benzodiazepine Hypnotics from 2021 to 2026.
    Chapter 3, the Non-benzodiazepine Hypnotics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Non-benzodiazepine Hypnotics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Non-benzodiazepine Hypnotics.
    Chapter 13, to describe Non-benzodiazepine Hypnotics research findings and conclusion.

    Buy now